Combourg

Researchers are evaluating the effectiveness of a hypnotherapy method called E2R in managing chronic insomnia in primary care. Chronic insomnia is commonly treated with hypnotic drugs in France, though these have notable side effects. Cognitive-behavioral therapy is recommended as a first-line non-drug treatment but is not widely used due to limited availability and time demands. The study aims to compare E2R hypnotherapy to standard care without hypnosis in patients with chronic insomnia. Patients will be randomly assigned to one of two groups: the E2R hypnosis group or the standard care control group. Those in the hypnosis group will receive four 30-minute hypnotherapy sessions over six weeks with a hypnotherapist located within 30 minutes of their home. The control group will receive the usual care by their general practitioner, which may include psychotherapy or medication but will exclude hypnosis. Both groups will have follow-up visits at three and six months after randomization. During the study, patients will complete questionnaires such as the Insomnia Severity Index and Pittsburgh Sleep Quality Index. Researchers will track use of psychotropic medications, any non-drug therapies, practice of self-hypnosis, events affecting sleep, and any adverse neuropsychiatric events. The main outcome measured is the severity of insomnia at six months. Safety and treatment effects will be assessed through these follow-ups, with the total study duration being six months.

Researchers are evaluating two blood tests, eLIFT and FibroMeter, to screen for advanced liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and/or alcoholic liver disease (ALD) in primary care settings. These chronic liver diseases are common and can lead to serious complications if advanced fibrosis is not detected early. General practitioners often find it challenging to identify patients with advanced fibrosis because routine exams and tests may appear normal. The study compares the eLIFT test, designed for easy use by general practitioners with simple calculation, to the more specialized FibroMeter test. Both tests are blood-based and aim to detect advanced liver fibrosis. Patients may also undergo elastography, a device-based liver stiffness measurement, or liver biopsy if needed. The study is conducted in primary care centers where patients with NAFLD and/or ALD will be screened using these tests. Participants provide blood samples and undergo clinical evaluations during the study. Researchers will measure how sensitive each test is in detecting advanced liver fibrosis. The study includes collecting blood samples at local laboratories and monitoring outcomes such as test sensitivity on the same day. The total participation timeframe includes initial screening and diagnostic testing procedures within one day.